NCT05364424 2025-12-01A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell LymphomaHoffmann-La RochePhase 1 Completed43 enrolled
NCT06792253 2025-01-24Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaBeBetter Med IncPhase 3 Recruiting416 enrolled
NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT06164327 2023-12-11Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaBeBetter Med IncPhase 1 Unknown75 enrolled
NCT02018861 2023-09-28A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)Incyte CorporationPhase 1/2 Completed88 enrolled 25 charts
NCT01618136 2023-06-18An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsEisai Inc.Phase 1/2 Completed41 enrolled
NCT02592876 2019-05-17Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaSeagen Inc.Phase 2 Terminated81 enrolled 15 charts
NCT03349346 2018-12-11Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsGilead SciencesPhase 1 Withdrawn
NCT00529503 2015-02-25A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCLSeagen Inc.Phase 2 Terminated151 enrolled